Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)

OBJECTIVES: To investigate the efficacy and safety of otilimab, an anti-granulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis and an inadequate response to conventional synthetic (cs) and biologic disease-modifying antirheumatic drugs (DMARDs) and/or...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C, Weinblatt, Michael E, McInnes, Iain B, Atsumi, Tatsuya, Strand, Vibeke, Takeuchi, Tsutomu, Bracher, Marguerite, Brooks, David, Davies, John, Goode, Christopher, Gupta, Anubha, Mukherjee, Sumanta, O’Shea, Ciara, Saurigny, Didier, Schifano, Lorrie A, Shelton, Celia, Smith, Julia E, Wang, Millie, Wang, Reena, Watts, Sarah, Fleischmann, Roy M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646837/
https://www.ncbi.nlm.nih.gov/pubmed/37696589
http://dx.doi.org/10.1136/ard-2023-224449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646837/
https://www.ncbi.nlm.nih.gov/pubmed/37696589
http://dx.doi.org/10.1136/ard-2023-224449

Ejemplares similares